157 related articles for article (PubMed ID: 35277656)
1. Dissection of molecular and histological subtypes of papillary thyroid cancer using alternative splicing profiles.
Park J; Kim D; Lee JO; Park HC; Ryu BY; Kim JH; Lee SH; Chung YJ
Exp Mol Med; 2022 Mar; 54(3):263-272. PubMed ID: 35277656
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of aberrant alternative splicing related to carcinogenesis and prognosis of papillary thyroid cancer.
Zheng X; Feng L; Yin Y; Yu C; He X; Zhu J; Zhang M; Yu J; Xu M
Aging (Albany NY); 2021 Oct; 13(19):23149-23168. PubMed ID: 34628367
[TBL] [Abstract][Full Text] [Related]
3. The lncRNA UNC5B-AS1 promotes proliferation, migration, and invasion in papillary thyroid cancer cell lines.
Wang Y; Bhandari A; Niu J; Yang F; Xia E; Yao Z; Jin Y; Zheng Z; Lv S; Wang O
Hum Cell; 2019 Jul; 32(3):334-342. PubMed ID: 30805847
[TBL] [Abstract][Full Text] [Related]
4. A 5'-tRNA halve, tiRNA-Gly promotes cell proliferation and migration via binding to RBM17 and inducing alternative splicing in papillary thyroid cancer.
Han L; Lai H; Yang Y; Hu J; Li Z; Ma B; Xu W; Liu W; Wei W; Li D; Wang Y; Zhai Q; Ji Q; Liao T
J Exp Clin Cancer Res; 2021 Jul; 40(1):222. PubMed ID: 34225773
[TBL] [Abstract][Full Text] [Related]
5. SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.
He J; Zhou M; Li X; Gu S; Cao Y; Xing T; Chen W; Chu C; Gu F; Zhou J; Jin Y; Ma J; Ma D; Zou Q
Oncogene; 2020 Mar; 39(13):2658-2675. PubMed ID: 32005974
[TBL] [Abstract][Full Text] [Related]
6. Role of global aberrant alternative splicing events in papillary thyroid cancer prognosis.
Lin P; He RQ; Huang ZG; Zhang R; Wu HY; Shi L; Li XJ; Li Q; Chen G; Yang H; He Y
Aging (Albany NY); 2019 Apr; 11(7):2082-2097. PubMed ID: 30986203
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of long noncoding RNA interactions reveals the potential role in progression of human papillary thyroid cancer.
You X; Zhao Y; Sui J; Shi X; Sun Y; Xu J; Liang G; Xu Q; Yao Y
Cancer Med; 2018 Nov; 7(11):5394-5410. PubMed ID: 30318850
[TBL] [Abstract][Full Text] [Related]
8. Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas.
Fluge O; Haugen DR; Akslen LA; Marstad A; Santoro M; Fusco A; Varhaug JE; Lillehaug JR
Oncogene; 2001 Feb; 20(7):885-92. PubMed ID: 11314023
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma.
Teng H; Mao F; Liang J; Xue M; Wei W; Li X; Zhang K; Feng D; Liu B; Sun Z
Theranostics; 2018; 8(16):4345-4358. PubMed ID: 30214625
[TBL] [Abstract][Full Text] [Related]
10. RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.
Khan MS; Qadri Q; Makhdoomi MJ; Wani MA; Malik AA; Niyaz M; Masoodi SR; Andrabi KI; Ahmad R; Mudassar S
Pathol Oncol Res; 2020 Jan; 26(1):507-513. PubMed ID: 30467698
[TBL] [Abstract][Full Text] [Related]
11. PDZK1 Interacting Protein 1 Promotes the Progression of Papillary Thyroid Cancer.
Wang K; Liu S; Tian Y; Liu C; Gui Z; Yu T; Zhang L
J Clin Endocrinol Metab; 2022 Aug; 107(9):2449-2461. PubMed ID: 35727731
[TBL] [Abstract][Full Text] [Related]
12. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
Pang R; Yang S
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive transcriptomic analysis of papillary thyroid cancer: potential biomarkers associated with tumor progression.
Hosseinkhan N; Honardoost M; Blighe K; Moore CBT; Khamseh ME
J Endocrinol Invest; 2020 Jul; 43(7):911-923. PubMed ID: 31965517
[TBL] [Abstract][Full Text] [Related]
14. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
15. Hsa_circ_0039411 promotes tumorigenesis and progression of papillary thyroid cancer by miR-1179/ABCA9 and miR-1205/MTA1 signaling pathways.
Yang Y; Ding L; Li Y; Xuan C
J Cell Physiol; 2020 Feb; 235(2):1321-1329. PubMed ID: 31270819
[TBL] [Abstract][Full Text] [Related]
16. Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma.
Stosic A; Fuligni F; Anderson ND; Davidson S; de Borja R; Acker M; Forte V; Campisi P; Propst EJ; Wolter NE; Chami R; Mete O; Malkin D; Shlien A; Wasserman JD
Cancer Res; 2021 Nov; 81(22):5625-5637. PubMed ID: 34535459
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
[TBL] [Abstract][Full Text] [Related]
18. Role of oncogene PIM-1 in the development and progression of papillary thyroid carcinoma: Involvement of oxidative stress.
Wen QL; Yi HQ; Yang K; Yin CT; Yin WJ; Xiang FY; Bao M; Shuai J; Song YW; Ge MH; Zhu X
Mol Cell Endocrinol; 2021 Mar; 523():111144. PubMed ID: 33383107
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of novel long intergenic non‑coding RNA LINC02454 is associated with a poor prognosis in papillary thyroid cancer.
Tan J; Liu L; Zuo Z; Song B; Cai T; Ding D; Lu Y; Ye X
Oncol Rep; 2020 Oct; 44(4):1489-1501. PubMed ID: 32945494
[TBL] [Abstract][Full Text] [Related]
20. Identifying the tumor-progressive gene expression profile in high-risk papillary thyroid cancer.
Shibata M; Inaishi T; Ichikawa T; Shimizu D; Soeda I; Takano Y; Takeuchi D; Tsunoda N; Kikumori T
Surg Today; 2021 Oct; 51(10):1703-1712. PubMed ID: 33733290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
